| Original language | English |
|---|---|
| Pages (from-to) | 191-202 |
| Number of pages | 12 |
| Journal | Pharmacoeconomics |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2017 |
Keywords
- PLACEBO-CONTROLLED PHASE-3
- SURVIVAL ANALYSIS
- DOUBLE-BLIND
Cite this
}
Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer : An Evidence Review Group Perspective of an NICE Single Technology Appraisal. / Ramaekers, Bram L. T.; Riemsma, Rob; Tomini, Florian; van Asselt, Thea; Deshpande, Sohan; Duffy, Steven; Armstrong, Nigel; Severens, Johan L.; Kleijnen, Jos; Joore, Manuela A.
In: Pharmacoeconomics, Vol. 35, No. 2, 02.2017, p. 191-202.Research output: Contribution to journal › Review article › Academic › peer-review
TY - JOUR
T1 - Abiraterone Acetate for the Treatment of Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
T2 - An Evidence Review Group Perspective of an NICE Single Technology Appraisal
AU - Ramaekers, Bram L. T.
AU - Riemsma, Rob
AU - Tomini, Florian
AU - van Asselt, Thea
AU - Deshpande, Sohan
AU - Duffy, Steven
AU - Armstrong, Nigel
AU - Severens, Johan L.
AU - Kleijnen, Jos
AU - Joore, Manuela A.
PY - 2017/2
Y1 - 2017/2
KW - PLACEBO-CONTROLLED PHASE-3
KW - SURVIVAL ANALYSIS
KW - DOUBLE-BLIND
U2 - 10.1007/s40273-016-0445-5
DO - 10.1007/s40273-016-0445-5
M3 - Review article
VL - 35
SP - 191
EP - 202
JO - Pharmacoeconomics
JF - Pharmacoeconomics
SN - 1170-7690
IS - 2
ER -